Department of Ultrasound, Xinqiao Hospital, Army Medical University, Chongqing, China.
General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, China.
Med Phys. 2021 Jul;48(7):3927-3935. doi: 10.1002/mp.14867. Epub 2021 Jul 19.
Ultrasound-targeted microbubble destruction (UTMD) has been widely applied to enhance chemotherapy of tumors, yet few studies have focused on the metastatic potential induced by UTMD. This study aimed to explore the metastasis of VX2 tumors after treatment with UTMD and chemotherapy.
Forty-four New Zealand rabbits bearing subcutaneous VX2 tumors were enrolled for the treatment of UTMD with chemotherapy. For UTMD, the tumors were insonated using two pulsing protocols of diagnostic ultrasound (DUS, VINNO and ECARE) with a mechanical index (MI) of 0.29-0.33, tone burst of 8.0 cycles, and frequencies of 3-4 MHz. A total dose of 2 ml SonoVue® was injected intermittently during 10-min UTMD exposure. The combination therapy was treated using doxorubicin (DOX, 2 mg/kg) and DUS, while the tumors treated using DOX only served as the control. Tumor size was measured using the tumor volume formula. Survival time was observed until animal death or the end of the study (120 days). Specific organs (lung, liver, kidney, and brain) were removed for metastatic evaluation.
There were no statistical differences in overall metastasis classification and individual organ metastases among all groups (P > 0.05). The tumor growth rate only showed inhibition on the 5th day (P < 0.01). The survival time did not demonstrate any significant difference between UTMD and chemotherapy only (P > 0.05).
UTMD using long-pulse DUS with commercial microbubbles did not pose a risk of metastasis enhancement in DOX chemotherapy.
超声靶向微泡破坏(UTMD)已广泛应用于增强肿瘤的化学疗法,但很少有研究关注 UTMD 诱导的转移潜能。本研究旨在探讨 UTMD 联合化疗治疗后 VX2 肿瘤的转移情况。
将 44 只荷皮下 VX2 肿瘤的新西兰兔纳入 UTMD 联合化疗治疗。对于 UTMD,使用两种诊断超声(DUS,VINNO 和 ECARE)的脉冲方案对肿瘤进行照射,机械指数(MI)为 0.29-0.33,声脉冲持续时间为 8.0 个周期,频率为 3-4 MHz。在 10 分钟的 UTMD 暴露过程中,间歇性地注射 2 ml SonoVue®。联合治疗采用多柔比星(DOX,2 mg/kg)和 DUS,而仅用 DOX 治疗的肿瘤作为对照。使用肿瘤体积公式测量肿瘤大小。观察存活时间,直到动物死亡或研究结束(120 天)。切除特定器官(肺、肝、肾和脑)进行转移评估。
各组之间的总体转移分类和个体器官转移无统计学差异(P>0.05)。肿瘤生长率仅在第 5 天显示出抑制(P<0.01)。UTMD 组与仅化疗组的存活时间无显著差异(P>0.05)。
使用商用微泡的长脉冲 DUS 的 UTMD 不会增加 DOX 化疗中转移增强的风险。